Evidence map›Paper›PMID 40121004›Full record

ArticleBMJ open quality2025

Reducing laboratory delays in blood culture pathogen identification: a quality improvement project.

Fenella D Halstead, Goran Pinjuh, Grazia Antonacci, Nathan Proudlove

Abstract read
In one paragraph

Article in BMJ open quality, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fenella D HalsteadMedical Microbiology, Wye Valley NHS Trust, Hereford, UK fenella.halstead@wvt.nhs.uk.ORCID http://orcid.org/0000-0002-2833-2926
Goran PinjuhMedical Microbiology, Wye Valley NHS Trust, Hereford, UK.ORCID http://orcid.org/0009-0001-6471-1093
Grazia AntonacciDepartment of Primary Care and Public Health, NIHR ARC NWL, Centre for Health Economics & Policy Innovation, Imperial College London, Imperial College Business School, London, UK.ORCID http://orcid.org/0000-0001-7742-8003
Nathan ProudloveAlliance Manchester Business School, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-1176-8088

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a medical emergency caused by bacteria in the bloodstream and a dysregulated immune response. It is important to identify the bacteria rapidly so that the patient receives effective antibiotics. Delays are associated with higher mortality levels and poorer clinical outcomes.Guidance requires full bacterial identification (ID) from bottle flagging positive, within 48 hours with older technology and 24 hours with modern platforms. Before this quality improvement project, we were using old technology including Analytical Profile Index (API) biochemical tests. Analysis highlighted very poor performance (mean 60 hours to ID), resulting in limited clinical utility and clinical incidents. There was great frustration among laboratory and clinical staff.This project aimed to reduce the time taken to obtain ID for positive blood cultures to meet the guidance within 6 months. Analysis led to a business case which helped secure funding for new equipment: a Matrix Assisted Laser Desorption Ionisation (MALDI) platform, to replace the time-consuming API process. MALDI uses time-of-flight mass spectrometry producing rapid ID of bacteria in minutes, indirectly (from agar plate colonies) or directly from blood.MALDI was introduced through two Plan-Do-Study-Act cycles, first with indirect analysis, then with direct. This spread the scientific staff training burden. The new process has dramatically reduced the mean time from flagging to pathogen ID to an average of 10.2 hours, and availability of ID within 24 hours has improved from 0% to 95%.We identified other change ideas for improvement (increasing staff availability and new technology for later stages), but these were parked due to time and funding pressures.Although there remain limitations (especially in terms of staffing hours and the onward communication of the ID result), the MALDI platform has revolutionised the sepsis service we can provide, so represents a substantial improvement in the quality of care that our patients can receive.

Indexed as

Blood CultureQuality ImprovementHumansSepsisSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTime FactorsDiagnostic ServicesLaboratory medicineQuality improvementSepsis

Identifiers

PMID40121004
PMCPMC11931963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.